<DOC>
	<DOCNO>NCT02429453</DOCNO>
	<brief_summary>The goal study determine whether PCC confers benefit FFP traumatic spontaneous intracranial hemorrhage respect multiple factor include time correction , absolute international normalize ratio correction amount , cost , need surgical intervention , radiographic bleed expansion prospective , randomize control trial .</brief_summary>
	<brief_title>FFP Versus PCC Intracranial Hemorrhage</brief_title>
	<detailed_description>Vitamin K antagonists general Coumadin particular remain common form outpatient anticoagulation patient today . Despite therapeutic benefit agent , bleed general intracranial bleeding particular significant risk associate medication . Intracranial bleed oral anticoagulation agent associate 20 % increase 30 day mortality versus non-anticoagulated control , rapid reversal vitamin K antagonists population show survival benefit . Historically , vitamin K antagonist reverse use fresh frozen plasma ( FFP ) transfusion , though effective , often incur delay due time require obtain type &amp; screen , thaw product , administer product patient . In 2013 , FDA approve 4-factor prothrombin complex ( PCC ) , concentrate factor II , VII , IX , X , protein C protein S use method correct vitamin K antagonist relate coagulopathy . Though large , prospective randomize control trial demonstrate efficacy safety general population all-comers bleeding , little literature regard benefit PCC versus FFP traumatic spontaneous intracranial hemorrhage population . Current standard care patient traumatic spontaneous intracranial hemorrhage vitamin K antagonists reverse effect agent FFP PCC . The choice agent use currently determine availability agent surgeon preference . For study , equal likelihood either treatment give . The goal study determine whether PCC confers benefit FFP traumatic spontaneous intracranial hemorrhage respect multiple factor include time correction , absolute international normalize ratio correction amount , cost , need surgical intervention , radiographic bleed expansion prospective , randomize control trial .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Intracranial Hemorrhages</mesh_term>
	<mesh_term>Intracranial Hemorrhage , Traumatic</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<criteria>Coumadin use INR 2.0 high arrival study center Evidence cranial image spontaneous intracranial hemorrhage , subdural hematoma , epidural hematoma , cerebral contusion , traumatic subarachnoid hemorrhage , traumatic intraparenchymal hemorrhage Unable obtain consent Estimated survival &lt; 24 hour Hypersensitivity 4 factor prothrombin complex concentrate Concomitant use novel vitamin K antagonists Religious/social prohibition receive blood product Need emergent , nonneurosurgical operative intervention Mechanical heart valve</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Warfarin</keyword>
	<keyword>Traumatic intracranial hemorrhage</keyword>
	<keyword>prothrombin complex concentrate</keyword>
	<keyword>fresh frozen plasma</keyword>
	<keyword>Spontaneous intracranial hemorrhage</keyword>
</DOC>